| 26.08 0.08 (0.31%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.46  |
1-year : | 35.57 |
| Resists | First : | 26.07 |
Second : | 30.46 |
| Pivot price | 25.57 |
|||
| Supports | First : | 24.73 |
Second : | 23.89 |
| MAs | MA(5) : | 25.86 |
MA(20) : | 25.39 |
| MA(100) : | 23.8 |
MA(250) : | 22.2 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 94 |
D(3) : | 88.2 |
| RSI | RSI(14): 77.4 |
|||
| 52-week | High : | 26.07 | Low : | 14.1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OLK ] has closed above the upper band by 1.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 26.1 - 26.17 | 26.17 - 26.26 |
| Low: | 25.76 - 25.86 | 25.86 - 25.96 |
| Close: | 25.91 - 26.06 | 26.06 - 26.22 |
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
Thu, 11 Jul 2024
Thermo Fisher Scientific Completes Acquisition of Olink - Technology Networks
Tue, 09 Jul 2024
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod - Yahoo Finance
Mon, 08 Jul 2024
Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher - GlobeNewswire
Wed, 03 Jul 2024
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery - GlobeNewswire
Mon, 13 May 2024
Olink reports first quarter 2024 financial results - GlobeNewswire
Mon, 25 Mar 2024
Olink reports fourth quarter and full year 2023 financial results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 124 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 66.4 (%) |
| Held by Institutions | 35.2 (%) |
| Shares Short | 2,530 (K) |
| Shares Short P.Month | 2,840 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.71 |
| Profit Margin | -19.8 % |
| Operating Margin | -86.8 % |
| Return on Assets (ttm) | -6.6 % |
| Return on Equity (ttm) | -7.1 % |
| Qtrly Rev. Growth | 4.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.37 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -41 (M) |
| PE Ratio | -96.6 |
| PEG Ratio | 0 |
| Price to Book value | 7.02 |
| Price to Sales | 18.97 |
| Price to Cash Flow | -76.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|